Global Blood Cancer Molecular Diagnostics 麻豆原创 Research Report 2023

Publication ID:

PB510231347

Publication Date:

October 30, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Blood Cancer Molecular Diagnostics market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Blood Cancer Molecular Diagnostics market research.
Key companies engaged in the Blood Cancer Molecular Diagnostics industry include Roche Diagnostics, Abbott, Thermo Fisher, Qiagen, Illumina, Agilent, Liferiver, Gpmedical and Zeesan, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Blood Cancer Molecular Diagnostics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Blood Cancer Molecular Diagnostics market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Blood Cancer Molecular Diagnostics market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Roche Diagnostics
Abbott
Thermo Fisher
Qiagen
Illumina
Agilent
Liferiver
Gpmedical
Zeesan
Berry Oncology
Annoroad
Segment by Type
Polymerase Chain Reaction
Molecular Hybridization
Biochip
Others
Segment by Application
Hospital
Third-Party Testing Agency
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Blood Cancer Molecular Diagnostics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Blood Cancer Molecular Diagnostics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Polymerase Chain Reaction
1.2.3 Molecular Hybridization
1.2.4 Biochip
1.2.5 Others
1.3 麻豆原创 by Application
1.3.1 Global Blood Cancer Molecular Diagnostics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Third-Party Testing Agency
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Blood Cancer Molecular Diagnostics 麻豆原创 Perspective (2018-2029)
2.2 Blood Cancer Molecular Diagnostics Growth Trends by Region
2.2.1 Global Blood Cancer Molecular Diagnostics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Blood Cancer Molecular Diagnostics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Blood Cancer Molecular Diagnostics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Blood Cancer Molecular Diagnostics 麻豆原创 Dynamics
2.3.1 Blood Cancer Molecular Diagnostics Industry Trends
2.3.2 Blood Cancer Molecular Diagnostics 麻豆原创 Drivers
2.3.3 Blood Cancer Molecular Diagnostics 麻豆原创 Challenges
2.3.4 Blood Cancer Molecular Diagnostics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Blood Cancer Molecular Diagnostics Players by Revenue
3.1.1 Global Top Blood Cancer Molecular Diagnostics Players by Revenue (2018-2023)
3.1.2 Global Blood Cancer Molecular Diagnostics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Blood Cancer Molecular Diagnostics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Blood Cancer Molecular Diagnostics Revenue
3.4 Global Blood Cancer Molecular Diagnostics 麻豆原创 Concentration Ratio
3.4.1 Global Blood Cancer Molecular Diagnostics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Blood Cancer Molecular Diagnostics Revenue in 2022
3.5 Blood Cancer Molecular Diagnostics Key Players Head office and Area Served
3.6 Key Players Blood Cancer Molecular Diagnostics Product Solution and Service
3.7 Date of Enter into Blood Cancer Molecular Diagnostics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Blood Cancer Molecular Diagnostics Breakdown Data by Type
4.1 Global Blood Cancer Molecular Diagnostics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Blood Cancer Molecular Diagnostics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Blood Cancer Molecular Diagnostics Breakdown Data by Application
5.1 Global Blood Cancer Molecular Diagnostics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Blood Cancer Molecular Diagnostics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Blood Cancer Molecular Diagnostics 麻豆原创 Size (2018-2029)
6.2 North America Blood Cancer Molecular Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Blood Cancer Molecular Diagnostics 麻豆原创 Size by Country (2018-2023)
6.4 North America Blood Cancer Molecular Diagnostics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Blood Cancer Molecular Diagnostics 麻豆原创 Size (2018-2029)
7.2 Europe Blood Cancer Molecular Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Blood Cancer Molecular Diagnostics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Blood Cancer Molecular Diagnostics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Blood Cancer Molecular Diagnostics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Blood Cancer Molecular Diagnostics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Blood Cancer Molecular Diagnostics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Blood Cancer Molecular Diagnostics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Blood Cancer Molecular Diagnostics 麻豆原创 Size (2018-2029)
9.2 Latin America Blood Cancer Molecular Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Blood Cancer Molecular Diagnostics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Blood Cancer Molecular Diagnostics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Blood Cancer Molecular Diagnostics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Blood Cancer Molecular Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Blood Cancer Molecular Diagnostics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Blood Cancer Molecular Diagnostics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche Diagnostics
11.1.1 Roche Diagnostics Company Detail
11.1.2 Roche Diagnostics Business Overview
11.1.3 Roche Diagnostics Blood Cancer Molecular Diagnostics Introduction
11.1.4 Roche Diagnostics Revenue in Blood Cancer Molecular Diagnostics Business (2018-2023)
11.1.5 Roche Diagnostics Recent Development
11.2 Abbott
11.2.1 Abbott Company Detail
11.2.2 Abbott Business Overview
11.2.3 Abbott Blood Cancer Molecular Diagnostics Introduction
11.2.4 Abbott Revenue in Blood Cancer Molecular Diagnostics Business (2018-2023)
11.2.5 Abbott Recent Development
11.3 Thermo Fisher
11.3.1 Thermo Fisher Company Detail
11.3.2 Thermo Fisher Business Overview
11.3.3 Thermo Fisher Blood Cancer Molecular Diagnostics Introduction
11.3.4 Thermo Fisher Revenue in Blood Cancer Molecular Diagnostics Business (2018-2023)
11.3.5 Thermo Fisher Recent Development
11.4 Qiagen
11.4.1 Qiagen Company Detail
11.4.2 Qiagen Business Overview
11.4.3 Qiagen Blood Cancer Molecular Diagnostics Introduction
11.4.4 Qiagen Revenue in Blood Cancer Molecular Diagnostics Business (2018-2023)
11.4.5 Qiagen Recent Development
11.5 Illumina
11.5.1 Illumina Company Detail
11.5.2 Illumina Business Overview
11.5.3 Illumina Blood Cancer Molecular Diagnostics Introduction
11.5.4 Illumina Revenue in Blood Cancer Molecular Diagnostics Business (2018-2023)
11.5.5 Illumina Recent Development
11.6 Agilent
11.6.1 Agilent Company Detail
11.6.2 Agilent Business Overview
11.6.3 Agilent Blood Cancer Molecular Diagnostics Introduction
11.6.4 Agilent Revenue in Blood Cancer Molecular Diagnostics Business (2018-2023)
11.6.5 Agilent Recent Development
11.7 Liferiver
11.7.1 Liferiver Company Detail
11.7.2 Liferiver Business Overview
11.7.3 Liferiver Blood Cancer Molecular Diagnostics Introduction
11.7.4 Liferiver Revenue in Blood Cancer Molecular Diagnostics Business (2018-2023)
11.7.5 Liferiver Recent Development
11.8 Gpmedical
11.8.1 Gpmedical Company Detail
11.8.2 Gpmedical Business Overview
11.8.3 Gpmedical Blood Cancer Molecular Diagnostics Introduction
11.8.4 Gpmedical Revenue in Blood Cancer Molecular Diagnostics Business (2018-2023)
11.8.5 Gpmedical Recent Development
11.9 Zeesan
11.9.1 Zeesan Company Detail
11.9.2 Zeesan Business Overview
11.9.3 Zeesan Blood Cancer Molecular Diagnostics Introduction
11.9.4 Zeesan Revenue in Blood Cancer Molecular Diagnostics Business (2018-2023)
11.9.5 Zeesan Recent Development
11.10 Berry Oncology
11.10.1 Berry Oncology Company Detail
11.10.2 Berry Oncology Business Overview
11.10.3 Berry Oncology Blood Cancer Molecular Diagnostics Introduction
11.10.4 Berry Oncology Revenue in Blood Cancer Molecular Diagnostics Business (2018-2023)
11.10.5 Berry Oncology Recent Development
11.11 Annoroad
11.11.1 Annoroad Company Detail
11.11.2 Annoroad Business Overview
11.11.3 Annoroad Blood Cancer Molecular Diagnostics Introduction
11.11.4 Annoroad Revenue in Blood Cancer Molecular Diagnostics Business (2018-2023)
11.11.5 Annoroad Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Roche Diagnostics
Abbott
Thermo Fisher
Qiagen
Illumina
Agilent
Liferiver
Gpmedical
Zeesan
Berry Oncology
Annoroad

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.